Zymeworks

Zymeworks presented at the Wells Fargo conference a hybrid strategy centered on Zanidatamab, license revenues and acquisitions, aiming to build sustainable, risk-adjusted cash flows. Zanidatamab received FDA approval for first-line treatment of gastric and gastroesophageal adenocarcinoma; Jazz Pharmaceuticals raises its peak sales forecast to $3–5 billion annually. The company financed buybacks and the Theravance acquisition with non-recourse debt (totaling $600 million) and plans to provide further guidance after the transaction closes. Future value drivers include potential Zanidatamab oncology indications, notably breast cancer, and the monetization of other pipeline assets. » Mais em de.investing.com

Zymeworks stock climbed to a new 52-week high of $30.75 after a year-to-date gain of 115.42% and a market capitalization of about $2.13 billion. Analysts maintain a largely positive consensus with price targets between $31 and $60; several firms raised targets or ratings. Zymeworks also received FDA approval for therapies with Ziihera for HER2-positive gastric and gastroesophageal adenocarcinoma, and a definitive acquisition agreement for Theravance Biopharma at $17 per share was announced, including a contingent value right for ampreloxetine. » Mais em de.investing.com

The U.S. approval of the cancer drug Ziihera triggers a contractual one-time payment of $0.25 billion to Zymeworks. H.C. Wainwright raised the price target from $51 to $55 and reaffirmed the buy recommendation. Zymeworks' business model combines in-house research with strategic partners and benefits from oncology growth trends. » Mais em finanzen.net